Opinion|Videos|April 18, 2025
Oral JAK Inhibitor Dose Escalation in Atopic Dermatitis Treatment
Experts discuss how clinical judgment guides the decision to increase the dose of a JAK inhibitor, considering factors like patient response and symptom severity, and how often dose escalation is implemented in practice based on individual patient needs.
Advertisement
Episodes in this series
Video content above is prompted by the following:
- With JAK inhibitor therapy, the dose can be increased if needed based on clinical judgment. How do you decide when a patient should increase the dose of their JAK inhibitor?
- How often do you increase to the higher dose of JAK inhibitors in practice?
Advertisement
Related to this article
Stress led all triggers, and a sense of an impending attack was the most reliable prodrome in patients with HAE-C1INH in the US HAEA Scientific Registry.
Stay updated with the latest healthcare breakthroughs, including the FDA approval of insulin efsitora alfa-gobe (Onswik).
Approval is based on 36-week data from BRAVE-AA-PEDS, in which 42% of patients on the 4 mg dose achieved a SALT score of 20 or less, compared with 5% on placebo.
The FDA approved once-daily oral zilurgisertib for FOP in patients aged 12 years and older after the phase 2 PROGRESS trial showed reduced new heterotopic ossification vs placebo.
Approval covers patients aged ≥2 years with frequently relapsing or steroid dependent disease in complete remission.
As the FDA weighs its first psychedelic approval, Sarah Norman, MPP, says training, credentialing, and reimbursement are lagging while patients are already asking.
Pranav Garimella discusses what a potential USPSTF kidney screening recommendation could mean for high-risk adults and primary care.
Andrea Murina, MD, weighs whether she would recommend medicine to her own children amid AI, physician burnout, and evolving residency training standards.
Advertisement
Advertisement
Trending on HCPLive
1
The Case for Routine Kidney Screening, With Pranav Garimella, MBBS, MPH
2
FDA Approves Obinutuzumab (Gazyva) for Idiopathic Nephrotic Syndrome
3
Zilurgisertib Receives FDA Approval for FOP in Patients 12 and Older
4
What The FDA Psychedelic Hearing Means for Psychiatrists
5